DK3072966T3 - Mitogenaktiveret proteinkinaseafhængig rekombinant vacciniavirus (MD-RVV) og anvendelse deraf - Google Patents
Mitogenaktiveret proteinkinaseafhængig rekombinant vacciniavirus (MD-RVV) og anvendelse deraf Download PDFInfo
- Publication number
- DK3072966T3 DK3072966T3 DK14864505.4T DK14864505T DK3072966T3 DK 3072966 T3 DK3072966 T3 DK 3072966T3 DK 14864505 T DK14864505 T DK 14864505T DK 3072966 T3 DK3072966 T3 DK 3072966T3
- Authority
- DK
- Denmark
- Prior art keywords
- rvv
- mitogen
- protein kinase
- vaccinia virus
- activated protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24161—Methods of inactivation or attenuation
- C12N2710/24162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013241299 | 2013-11-21 | ||
| PCT/JP2014/081484 WO2015076422A1 (ja) | 2013-11-21 | 2014-11-20 | ***促進因子活性化タンパク質キナーゼ依存性組換えワクシニアウイルス（md-rvv)及びその使用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3072966T3 true DK3072966T3 (da) | 2020-03-23 |
Family
ID=53179679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14864505.4T DK3072966T3 (da) | 2013-11-21 | 2014-11-20 | Mitogenaktiveret proteinkinaseafhængig rekombinant vacciniavirus (MD-RVV) og anvendelse deraf |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9809803B2 (da) |
| EP (1) | EP3072966B1 (da) |
| JP (1) | JP6378200B2 (da) |
| KR (1) | KR102197374B1 (da) |
| CN (2) | CN110527670A (da) |
| CA (1) | CA2931294C (da) |
| DK (1) | DK3072966T3 (da) |
| WO (1) | WO2015076422A1 (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6452266B2 (ja) * | 2015-07-22 | 2019-01-16 | 国立大学法人鳥取大学 | ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子 |
| EP3480307B1 (en) * | 2016-05-30 | 2021-06-23 | Astellas Pharma Inc. | New genetically-modified vaccinia virus |
| US10888594B2 (en) | 2016-05-30 | 2021-01-12 | National University Corporation Tottori University | Genetically engineered vaccinia viruses |
| US20190336552A1 (en) | 2016-05-30 | 2019-11-07 | Astellas Pharma Inc. | Genetically engineered vaccinia viruses |
| US20190367886A1 (en) * | 2016-07-13 | 2019-12-05 | National University Corporation Tottori Tottori University | Method for producing vaccinia virus expressing foreign gene |
| JP7274138B2 (ja) * | 2017-11-30 | 2023-05-16 | アステラス製薬株式会社 | Ｓｃｒ欠失ワクシニアウイルス |
| JP7034818B2 (ja) * | 2018-04-19 | 2022-03-14 | Ｋｍバイオロジクス株式会社 | 増殖性ヘルパーワクシニアウイルスを使用するポックスウイルスの製造方法 |
| JP7484717B2 (ja) | 2018-09-26 | 2024-05-16 | アステラス製薬株式会社 | 腫瘍溶解性ワクシニアウイルスと免疫チェックポイント阻害剤との併用によるがん療法並びにこれに用いるための医薬組成物及び組合せ医薬 |
| CN109750056A (zh) * | 2019-01-07 | 2019-05-14 | 西安医学院 | 去除天坛株vgf基因的打靶质粒及其制备方法 |
| WO2020148612A1 (en) | 2019-01-14 | 2020-07-23 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| US11685904B2 (en) | 2019-02-14 | 2023-06-27 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| EP3970740A4 (en) | 2019-05-14 | 2023-10-18 | National University Corporation Tottori University | CELL FUSION-INDUCING VACCINIA VIRUS AND USE THEREOF |
| CN114364792A (zh) * | 2019-08-09 | 2022-04-15 | Km生物医药股份公司 | 溶瘤牛痘病毒 |
| US20220290179A1 (en) | 2019-08-29 | 2022-09-15 | Astellas Pharma Inc. | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof |
| IL293627A (en) | 2019-12-12 | 2022-08-01 | Ignite Immunotherapy Inc | Variant of oncolytic vaccinia virus and methods of using it |
| CA3167002A1 (en) | 2020-01-09 | 2021-07-15 | Pfizer Inc. | Recombinant vaccinia virus |
| AU2021310520A1 (en) | 2020-07-14 | 2023-02-16 | Pfizer Inc. | Recombinant vaccinia virus |
| WO2022107705A1 (ja) | 2020-11-17 | 2022-05-27 | 国立大学法人鳥取大学 | 新規遺伝子組換えワクシニアウイルス及びその利用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2325321A1 (en) | 1999-05-28 | 2011-05-25 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| WO2005054451A1 (ja) | 2003-12-05 | 2005-06-16 | Hokkaido Technology Licensing Office Co., Ltd. | 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター |
| CA2795695A1 (en) | 2010-04-09 | 2011-10-13 | The University Of Tokyo | Microrna-controlled recombinant vaccinia virus and use thereof |
| US20130302367A1 (en) * | 2010-10-22 | 2013-11-14 | Hisatoshi Shida | Virus vector for prime/boost vaccines, which comprises vaccinia virus vector and sendai virus vector |
| EA201301173A1 (ru) * | 2011-04-15 | 2015-08-31 | Дженелюкс Корпорейшн | Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования |
| FI20115914L (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| JP5935130B2 (ja) | 2012-05-20 | 2016-06-15 | 香蘭産業株式会社 | イネ科植物灰の製造方法 |
-
2014
- 2014-11-20 JP JP2015549229A patent/JP6378200B2/ja active Active
- 2014-11-20 CN CN201910806504.5A patent/CN110527670A/zh active Pending
- 2014-11-20 KR KR1020167016591A patent/KR102197374B1/ko active IP Right Grant
- 2014-11-20 EP EP14864505.4A patent/EP3072966B1/en active Active
- 2014-11-20 CN CN201480063990.1A patent/CN105765062B/zh active Active
- 2014-11-20 DK DK14864505.4T patent/DK3072966T3/da active
- 2014-11-20 WO PCT/JP2014/081484 patent/WO2015076422A1/ja active Application Filing
- 2014-11-20 CA CA2931294A patent/CA2931294C/en active Active
- 2014-11-20 US US15/038,145 patent/US9809803B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105765062B (zh) | 2020-12-11 |
| CN105765062A (zh) | 2016-07-13 |
| CN110527670A (zh) | 2019-12-03 |
| KR20160079901A (ko) | 2016-07-06 |
| JP6378200B2 (ja) | 2018-08-22 |
| CA2931294C (en) | 2022-05-31 |
| CA2931294A1 (en) | 2015-05-28 |
| EP3072966B1 (en) | 2020-01-08 |
| EP3072966A4 (en) | 2017-04-19 |
| EP3072966A1 (en) | 2016-09-28 |
| KR102197374B1 (ko) | 2020-12-31 |
| JPWO2015076422A1 (ja) | 2017-03-16 |
| US20160281066A1 (en) | 2016-09-29 |
| WO2015076422A1 (ja) | 2015-05-28 |
| US9809803B2 (en) | 2017-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3072966T3 (da) | Mitogenaktiveret proteinkinaseafhængig rekombinant vacciniavirus (MD-RVV) og anvendelse deraf | |
| IL276106A (en) | Garp-binding proteins and their uses | |
| DK3052516T3 (da) | PCV2-ORF2-proteinvariant og viruslignende partikler sammensat deraf | |
| DK3393505T3 (da) | Rekombinante zika-vacciner | |
| DK3019533T3 (da) | Dobbeltspiraliserede immunoglobulinfusionproteiner og sammensætninger deraf | |
| DK3027204T3 (da) | Flerdelte signaleringsproteiner og anvendelser deraf | |
| DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
| DK3480307T3 (da) | Ny genetisk modificeret vacciniavirus | |
| DK3235830T3 (da) | Interleukin-15-proteinkompleks og anvendelse deraf | |
| DK2951203T3 (da) | Heterodimere proteiner | |
| DK3686280T3 (da) | Carbohydratdegraderende polypeptid og anvendelser deraf | |
| DK3114145T3 (da) | Anti human interleukin-1-receptor-assessory-protein (il1rap) antistoffer og anvendelser deraf | |
| DK2970460T3 (da) | Anti-IL-33-antistoffer og anvendelser deraf | |
| DK2968443T3 (da) | Hepcidinanaloger og anvendelser deraf | |
| DK2970464T3 (da) | Anti-lag-3-bindende proteiner | |
| DK3043784T3 (da) | Arylethere og anvendelser deraf | |
| DK3498292T3 (da) | Uspa2-proteinkonstruktioner og anvendelser deraf | |
| DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
| DK3041857T3 (da) | Protein a-kromatografi | |
| DK2962100T3 (da) | Tuberkulosebiomarkører og anvendelser deraf | |
| DK3029038T3 (da) | Tetrazolinonforbindelse og anvendelse deraf | |
| SG11201900439XA (en) | Recombinant vaccinia virus and use thereof | |
| DK3290441T3 (da) | Rgma-bindingsprotein og anvendelse deraf | |
| DK3434760T3 (da) | Fremgangsmåder til forøgelse af mannose-indholdet i rekombinante proteiner | |
| DK2983704T3 (da) | Fusionspolypeptider og vacciner |